Transapical implantation of a new second-generation transcatheter heart valve in patients with pure aortic regurgitation: a preliminary report.

Transcatheter aortic valve implantation (TAVI) has become an effective treatment option for high-risk or inoperable patients with aortic stenosis. However, experience with TAVI for non-calcified aortic regurgitation is still limited. The new J-Valve(™) system is a new second-generation TAVI device that is designed for transapical implantation. It is characterized by three U-shaped, anatomically oriented devices-'graspers' that could facilitate intuitive 'self-positioning' valve implantation and provide extra-radial fixation by embracing the native valve leaflets. Here, we reported the initial experience of TAVI in high-risk patients with pure aortic regurgitation using the J-Valve(™) system.